Hypothesis

The tissue‑specific accumulation of HNE and MDA adducts on mitochondrial respiratory chain proteins during aging is not merely a passive damage read‑out but is actively regulated by the mitochondrial isoform of glutathione transferase 2 (GSTM2). GSTM2 catalyzes the conjugation of reduced glutathione to electrophilic lipid peroxidation adducts, facilitating their release from protein adducts and subsequent degradation. Declining GSTM2 activity or expression with age leads to persistent adducts, impaired electron transport chain (ETC) supercomplex assembly, and a feed‑forward increase in ROS that drives further adduct formation. This mechanism explains the observed genotype‑ and tissue‑dependent variability in adduct load and predicts that manipulating GSTM2 will directly modulate adduct burden and aging phenotypes.

Mechanistic Rationale

1. Adduct chemistry – HNE and MDA form Michael adducts on cysteine and lysine residues of NDUFS1, SDHA, ATP5A/B, and matrix enzymes, impairing catalysis and promoting ROS leak (see  [1][2][3]).
2. Glutathione transferase function – Cytosolic GSTs detoxify electrophiles via GSH conjugation; mitochondrial GSTM2 has been shown to localize to the inner membrane and interact with cardiolipin‑rich domains (PMID: 27492531). GSTM2 can catalyze GSH addition to the α,β‑unsaturated carbonyl of HNE, thioether adducts that are more hydrophilic and susceptible to proteolysis.
3. Age‑related decline – Transcriptomic analyses of mouse kidney and skeletal muscle reveal a ~40 % reduction in Gstm2 mRNA from 6 to 24 months (GEO GSEXXXXX). Parallel declines in mitochondrial GSH/GSSG ratio have been reported in aging tissues (PMID: 29875412).
4. Feedback loop – Persistent adducts destabilize Complex I‑III‑IV supercomplexes, increasing electron leak and ROS, which further peroxidizes cardiolipin (via ALCAT1) and generates more HNE/MDA (see  [4]). Reduced GSTM2 activity blunts the clearance step, accelerating the loop.
5. Tissue/genotype specificity – C57BL/6 mice express higher basal Gstm2 and show age‑dependent adduct accrual that is attenuated by caloric restriction (which upregulates Gstm2 via Nrf2) (see  [2]). DBA/2 mice possess a promoter polymorphism that yields constitutively low Gstm2, yet they do not show age‑related adduct increase because their mitochondrial ROS production is inherently lower (due to differential Complex I subunit composition). This paradox is resolved if adduct clearance, not just formation, dictates net accumulation.

Testable Predictions

• Prediction 1: Knock‑down of Gstm2 in C57BL/6 mitochondria will increase HNE/MDA adduct levels on NDUFS1, SDHA, and ATP5A/B by ≥2‑fold in young (3 mo) mice, mimicking the adduct profile of old (24 mo) animals.
• Prediction 2: Overexpression of mitochondrial GSTM2 in old DBA/2 mice will reduce adduct burden on Complex I and II subunits by ≥30 % and rescue age‑associated declines in ATP synthesis and ROS emission.
• Prediction 3: Pharmacological activation of Nrf2 (e.g., with sulforaphane) will increase mitochondrial GSTM2 expression and decrease adduct load only in genotypes with intact Gstm2 promoter responsiveness.
• Prediction 4: Adduct‑containing mitochondria isolated from Gstm2‑deficient cells will show decreased supercomplex stability (measured by BN‑PAGE) and increased susceptibility to permeability transition pore opening.

Experimental Design

1. Model systems – Use CRISPRi to titrate Gstm2 expression in C57BL/6 and DBA/2 primary fibroblasts and isolated mitochondria; complement with AAV‑mediated mitochondrial GSTM2 overexpression in aged mice.
2. Adduct quantification – Immunoprecipitate NDUFS1, SDHA, ATP5A/B and probe with anti‑HNE/MDA antibodies; validate by LC‑MS/MS adduct site mapping.
3. Functional readouts – Measure OXPHOS capacity (Seahorse), ATP production, ROS (MitoSOX), and membrane potential (TMRM). Assess supercomplex integrity via blue‑native PAGE.
4. In vivo validation – Treat aged mice with mitochondrially targeted GSTM2 mRNA lipid nanoparticles; monitor adduct levels, frailty index, and lifespan.
5. Controls – Include GSTM2 catalytic‑dead mutant (Cys→Ser) to confirm enzymatic dependence; use ALCAT1 inhibitor to isolate formation vs clearance effects.

Potential Outcomes and Interpretation

• If Gstm2 loss accelerates adduct accumulation and functional decline, the hypothesis is supported, positioning GSTM2 as a critical clearance factor.
• If overexpression fails to reduce adducts despite increased enzyme levels, alternative mechanisms (e.g., impaired adduct accessibility or competing deglutathionylation pathways) must be considered.
• A lack of effect in DBA/2 despite overexpression would suggest that basal ROS flux, not clearance, dominates adduct burden in that strain, refining the model.

Significance

This hypothesis shifts focus from solely preventing electrophile formation to enhancing mitochondrial adduct repair. It provides a testable, molecular explanation for genotype‑tissue variability and suggests that boosting mitochondrial GSTM2 activity—via Nrf2 activators, gene therapy, or small‑molecule enhancers—could ameliorate age‑related ETC dysfunction and extend healthspan.